Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naïve
T cell activation and effector differentiation. They are, likewise, involved in the induction and …

Gene therapy protocols require robust and long-term gene expression. For two decades,
retrovirus family vectors have offered several attractive properties as stable gene-delivery …

Although the earliest—rudimentary—attempts at exploiting the immune system for cancer
therapy can be traced back to the late 18th Century, it was not until the past decade that …

Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component
of the immune system's role in the recognition, elimination, and tolerance of cancer. The …

De novo regeneration of immunity is a major problem after allogeneic hematopoietic stem
cell transplantation (HCT). HCT modeling in severely compromised immune-deficient …

Monocyte-derived conventional dendritic cells (ConvDCs) loaded with melanoma antigens
showed modest responses in clinical trials. Efficacy studies were hampered by difficulties in …

Lentiviral vectors (LVs) developed in the past two decades for research and pre-clinical
purposes have entered clinical trials with remarkable safety and efficacy performances …

Complications due to HCMV infection or reactivation remain a challenging clinical problem
in immunocompromised patients, mainly due to insufficient or absent T‐cell functionality …

Background aims Dendritic cell (DC)-tumor cell hybrids have been used clinically in cancer
immunotherapy, but their advantage over the simple mixture of tumor cells and DCs is still a …

Dendritic cell (DC) vaccines are an immunotherapeutic approach to cancer treatment that
use the antigen-presentation machinery of DCs to activate an endogenous anti-tumor …